Patents Examined by Elly-Gerald Stoica
  • Patent number: 10314890
    Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 11, 2019
    Assignees: ASTELLAS PHARMA INC., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
  • Patent number: 10317415
    Abstract: The disclosure relates to the identification of salivary biomarkers for diagnosis and monitoring of type 2 diabetes in a subject. Also provided are methods for noninvasively diagnosing and monitoring type 2 diabetes in a subject. More particularly, the expression of salivary biomarkers, including MUC-1, MUC-2, MUC-4, and MUC-5B, are highly associated with A1C level in African American patients with type 2 diabetes.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: June 11, 2019
    Assignee: Howard University
    Inventors: Xinbin Gu, Grace Robinson
  • Patent number: 10308719
    Abstract: Provided are specific binding molecules, or fragments thereof, that bind to an epitope of IL13R?2, a receptor polypeptide preferentially found on the surface of cancer cells rather than healthy cells. Exemplary specific binding molecules are bispecific binding molecules that comprise a fragment of an IL13R?2 binding molecule and a peptide providing a second function providing a signaling function of the signaling domain of a T cell signaling protein, a peptide modulator of T cell activation, or an enzymatic component of a labeling system. Also provided are polynucleotides encoding such a specific binding molecule (e.g., bispecific binding molecule), vectors, host cells, pharmaceutical compositions and methods of preventing, treating or ameliorating a symptom associated with a cancer disease such as a solid tumor disease (e.g., glioblastoma multiforme).
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: June 4, 2019
    Assignee: THE UNIVERSITY OF CHICAGO
    Inventors: Irina V. Balyasnikova, Maciej S. Lesniak
  • Patent number: 10307455
    Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 4, 2019
    Assignees: Acceleron Pharma Inc., Adimab, LLC
    Inventors: Ravindra Kumar, Jonathan Belk, Asya Grinberg, Dianne Sako, Roselyne Castonguay
  • Patent number: 10301392
    Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: May 28, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: John Chen, Johan Fransson, Natalie Fursov, Damon Hamel, Thomas Malia, Galina Obmolova, Tatiana Ort, Michael Rycyzyn, Michael Scully, Raymond Sweet, Alexey Teplyakov, John Wheeler, Juan Carlos Almagro
  • Patent number: 10300076
    Abstract: Methods are directed to the treatment of subjects with prostate cancer, in particular those with castration resistant prostate cancer, with glucocorticoid receptor antagonists. The prostate cancer may be one that has become resistant to androgen deprivation therapy, for example, by increase in glucocorticoid receptor expression and/or activity.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: May 28, 2019
    Assignee: The University of Chicago
    Inventors: Russell Z. Szmulewitz, Suzanne D. Conzen
  • Patent number: 10293043
    Abstract: Methods of treating subjects having diseases, disorders, or conditions, including disorders associated with cholesterol homeostasis, responsive to agents modulating Kupffer cell function, including methods of administration and dosing regimens associated therewith, are provided. Methods of treating subjects having liver diseases, disorders, or conditions, including non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, with an IL-10 agent are also provided.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: May 21, 2019
    Assignee: Armo Biosciences, Inc.
    Inventors: John Brian Mumm, Ivan Ho Chan
  • Patent number: 10287357
    Abstract: The present invention provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human IL1RAP. The invention further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: May 14, 2019
    Assignee: Cantargia AB
    Inventors: Helena Ågerstam, Thoas Fioretos, Marcus Järås, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Agneta Svedberg, Karin von Wachenfeldt
  • Patent number: 10286064
    Abstract: The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of augmenting an immune response in a mammal, and methods of treating a disease in a mammal utilizing the vaccine compositions.
    Type: Grant
    Filed: June 13, 2013
    Date of Patent: May 14, 2019
    Assignees: PDS Biotechnology Corporation, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SEC. OF THE DEPT. OF HEALTH AND HUMAN SERVICES
    Inventors: Kenya Johnson, Eric Jacobson, Frank Bedu-Addo, Mikayel Mkrtichyan, Samir N. Khleif
  • Patent number: 10286039
    Abstract: The invention relates methods of using a retinoid agonist and a G-CSF or an analog thereof to treat, prevent, reduce the likelihood of having, reduce the severity of and/or slow the progression of a condition in a subject. The retinoid agonist and the G-CSF or the analog thereof may be provided in a single composition or in separate compositions. A therapeutically effective amount of the retinoid agonist and the G-CSF or the analog thereof may be administered to the subject concurrently or sequentially. Conditions treatable with the methods and compositions include but are not limited to various forms of neutropenia and microbial infections. The invention also relates to methods for determining the efficacy of the treatments described herein.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: May 14, 2019
    Assignee: Children's Hospital Los Angeles
    Inventor: Lingtao Wu
  • Patent number: 10286070
    Abstract: A method of treating cancer or metastasis is provided involving administering at least one oncostatin M (OSM) antagonist to a subject, wherein the subject has been diagnosed with cancer. Administration of an OSM antagonist such as a small molecule pharmaceutical is provided as well as an anti-OSM antibody, an anti-OSM aptamer, and an OSM mRNA antagonist. The OSM antagonists were found to inhibit or prevent tumor cell detachment, proliferation and metastasis in several cancer types.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: May 14, 2019
    Assignees: Boise State University, Idaho State University
    Inventors: Cheryl Jorcyk, Dong Xu
  • Patent number: 10279041
    Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 7, 2019
    Assignee: Hanmi Pharm Co. Ltd.
    Inventors: Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon
  • Patent number: 10266603
    Abstract: The invention includes method, pharmaceutical compositions and uses thereof for treating patients with Papillary Thyroid Carcinoma (PTC) using a Platelet Derived Growth Factor Receptor Alpha (PDGFRA) inhibitor. The PDGFRA inhibitor is preferably an antibody specific to PDGFRA and causes an increase in the sensitivity level of PTC cells to radioiodine treatment. Moreover, the antibody can be used in combination with other PDGFRA inhibitors such as tyrosine kinase inhibitors and RNA interference molecules.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: April 23, 2019
    Assignee: The Governors of the University of Alberta
    Inventors: Todd McMullen, Ana Lopez-Campistrous, David Williams
  • Patent number: 10246750
    Abstract: The invention provides to PKN1 gene fusions, PKN1 fusion proteins, and fragments of those genes and polypeptides. The invention further provides methods of diagnosing and treating diseases or disorders associated with PKN1 fusions, such as conditions mediated by aberrant PKN1 expression or activity, or over expression of PKN1.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: April 2, 2019
    Assignee: Blueprint Medicines Corporation
    Inventors: Nicolas Stransky, Joseph L. Kim
  • Patent number: 10221244
    Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: March 5, 2019
    Assignees: Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
    Inventors: Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
  • Patent number: 10208355
    Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: February 19, 2019
    Assignee: Genentech, Inc.
    Inventors: Carlos Bais, Richard Bourgon, Thomas Sandmann
  • Patent number: 10202432
    Abstract: A dual targeting drug carrier is provided. The dual targeting drug carrier comprises a first targeting molecule and a second targeting molecule, wherein the targeting molecule comprises peptide, protein or antibody. The targeting molecule can bind to specific receptors, proteins, or glycoproteins to recognize the specific tumor cells, tissues, or organs. The dual targeting drug carriers are further conjugated with imaging agents, radioactive molecules (radiopharmaceuticals, isotopes, or chemotherapeutic drugs) or nanoparticles to form a conjugate.
    Type: Grant
    Filed: November 27, 2015
    Date of Patent: February 12, 2019
    Assignee: NATIONAL YANG-MING UNIVERSITY
    Inventors: Cheng Allen Chang, Keng-Li Lan, Hsin-Ell Wang, Shun-Fu Chang, Jia-Je Li, Pei-Chia Chan
  • Patent number: 10201592
    Abstract: Cancer is a complex group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. Described herein are compositions and methods for the treatment of cancer.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: February 12, 2019
    Assignee: THE PACIFIC HEART, LUNG, & BLOOD INSTITUTE
    Inventors: Raymond Wong, Robert Cameron
  • Patent number: 10195274
    Abstract: Methods of modulating immune responses in subjects having oncology- and immune-related diseases, disorders and conditions by the administration of an IL-10 agent, including pegylated IL-10.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: February 5, 2019
    Assignee: Armo Biosciences Inc.
    Inventors: John Brian Mumm, Ivan Ho Chan
  • Patent number: 10184002
    Abstract: The present invention provides compositions and methods relating to antigen binding proteins against IL-21 receptor.
    Type: Grant
    Filed: March 1, 2016
    Date of Patent: January 22, 2019
    Assignee: AMGEN INC.
    Inventors: Marc A. Gavin, Ai Ching Lim